Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JW2202 Powder for Inhalation in COPD (Phase II crossover)
CTR20234155Phase 2Completed
- Sponsor
- Shandong Jingwei Pharmaceutical
- Start
- Dec 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of indacaterol acetate + glycopyrronium bromide + mometasone furoate in chronic obstructive pulmonary disease (COPD), sponsored by Shandong Jingwei Pharmaceutical. Started Dec 2023; status: completed.
02
Drugs
indacaterol acetate + glycopyrronium bromide + mometasone furoate
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20234155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234155.